All Static Circularly Symmetric Perfect Fluid Solutions of 2+1 Gravity

Via a straightforward integration of the Einstein equations with cosmological constant, all static circularly symmetric perfect fluid 2+1 solutions are derived. The structural functions of the metric depend on the energy density, which remains in general arbitrary. Spacetimes for fluids fulfilling linear and polytropic state equations are explicitly derived; they describe, among others, stiff matter, monatomic and diatomic ideal gases, nonrelativistic degenerate fermions, incoherent and pure radiation. As a by--product, we demonstrate the uniqueness of the constant energy density perfect fluid within the studied class of metrics. A full similarity of the perfect fluid solutions with constant energy density of the 2+1 and 3+1 gravities is established.Comment: revtex4, 8 page

Multi-wavelength interferometry of evolved stars using VLTI and VLBA

We report on our project of coordinated VLTI/VLBA observations of the atmospheres and circumstellar environments of evolved stars. We illustrate in general the potential of interferometric measurements to study stellar atmospheres and envelopes, and demonstrate in particular the advantages of a coordinated multi-wavelength approach including near/mid-infrared as well as radio interferometry. We have so far made use of VLTI observations of the near- and mid-infrared stellar sizes and of concurrent VLBA observations of the SiO maser emission. To date, this project includes studies of the Mira stars S Ori and RR Aql as well as of the supergiant AH Sco. These sources all show strong silicate emission features in their mid-infrared spectra. In addition, they each have relatively strong SiO maser emission. The results from our first epochs of S Ori measurements have recently been published and the main results are reviewed here. The S Ori maser ring is found to lie at a mean distance of about 2 stellar radii, a result that is virtually free of the usual uncertainty inherent in comparing observations of variable stars widely separated in time and stellar phase. We discuss the status of our more recent S Ori, RR Aql, and AH Sco observations, and present an outlook on the continuation of our project.Comment: 9 pages, to appear in the proceedings of the ESO workshop "The Power of Optical/IR Interferometry: Recent Scientific Results and 2nd Generation VLTI Instrumentation", ESO Astrophysics Symposi

Measurement of the Charged Multiplicities in b, c and Light Quark Events from Z0 Decays

Average charged multiplicities have been measured separately in $b$, $c$ and light quark ($u,d,s$) events from $Z^0$ decays measured in the SLD experiment. Impact parameters of charged tracks were used to select enriched samples of $b$ and light quark events, and reconstructed charmed mesons were used to select $c$ quark events. We measured the charged multiplicities: $\bar{n}_{uds} = 20.21 \pm 0.10 (\rm{stat.})\pm 0.22(\rm{syst.})$, $\bar{n}_{c} = 21.28 \pm 0.46(\rm{stat.}) ^{+0.41}_{-0.36}(\rm{syst.})$ $\bar{n}_{b} = 23.14 \pm 0.10(\rm{stat.}) ^{+0.38}_{-0.37}(\rm{syst.})$, from which we derived the differences between the total average charged multiplicities of $c$ or $b$ quark events and light quark events: $\Delta \bar{n}_c = 1.07 \pm 0.47(\rm{stat.})^{+0.36}_{-0.30}(\rm{syst.})$ and $\Delta \bar{n}_b = 2.93 \pm 0.14(\rm{stat.})^{+0.30}_{-0.29}(\rm{syst.})$. We compared these measurements with those at lower center-of-mass energies and with perturbative QCD predictions. These combined results are in agreement with the QCD expectations and disfavor the hypothesis of flavor-independent fragmentation.Comment: 19 pages LaTex, 4 EPS figures, to appear in Physics Letters

GLOSTAR — Radio Source Catalog II: 28◦ < l < 36◦ and |b| < 1◦,VLA B-configuration

As part of the Global View on Star Formation (GLOSTAR) survey we have used the Karl G. Jansky Very Large Array (VLA) in its B-configuration to observe the part of the Galactic plane between longitudes of 28◦ and 36◦ and latitudes from −1◦ to +1◦ at the C-band (4–8 GHz). To reduce the contamination of extended sources that are not well recovered by our coverage of the (u, v)-plane we discarded short baselines that are sensitive to emission on angular scales < 4′′. The resulting radio continuum images have an angular resolution of 1.′′0, and a sensitivity of ∼ 60 μJy beam−1; making it the most sensitive radio survey covering a large area of the Galactic plane with this angular resolution. An automatic source extraction algorithm was used in combination with visual inspection to identify a total of 3325 radio sources. A total of 1457 radio sources are ≥ 7σ and comprise our highly reliable catalog; 72 of these are grouped as 22 fragmented sources, e.g., multiple components of an extended and resolved source. To explore the nature of the catalogued radio sources we searched for counterparts at millimeter and infrared wavelengths. Our classification attempts resulted in 93 H ii region candidates, 104 radio stars, 64 planetary nebulae, while most of the remaining radio sources are suggested to be extragalactic sources. We investigated the spectral indices (α, S ν ∝ να) of radio sources classified as H ii region candidates and found that many have negative values. This may imply that these radio sources represent young stellar objects that are members of the star clusters around the high mass stars that excite the H ii regions, but not these H ii regions themselves. By comparing the peak flux densities from the GLOSTAR and CORNISH surveys we have identified 49 variable radio sources, most of them with an unknown nature. Additionally, we provide the list of 1866 radio sources detected within 5 to 7σ levels

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation &lt;92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p&lt;0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p&lt;0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research